Overview
Progressive cavitating leukoencephalopathy (PCL) is an extremely rare inherited neurological disorder characterized by progressive white matter deterioration (leukoencephalopathy) with the formation of cystic cavities (cavitations) in the brain. The disease primarily affects the central nervous system, with MRI findings showing diffuse white matter abnormalities and progressive cystic degeneration predominantly in the cerebral and cerebellar white matter. PCL has been associated with mutations in genes involved in mitochondrial function, including APOPT1 (also known as C14orf153) and genes encoding mitochondrial respiratory chain complex components such as NDUFS1 and other mitochondrial-related genes. The ICD-10 classification under E75.2 reflects its categorization among sphingolipidoses and other lipid storage disorders, though the primary pathology relates to mitochondrial dysfunction affecting white matter integrity. Clinical features typically include progressive motor deterioration, spasticity, ataxia, cognitive decline, and in some cases seizures. Affected individuals may initially develop normally before experiencing neurological regression. The severity and rate of progression can vary, with some patients presenting in infancy or early childhood with rapid decline, while others may have a more protracted course. Additional features may include dystonia, visual impairment, and difficulty with speech and swallowing as the disease advances. There is currently no cure or disease-specific treatment for progressive cavitating leukoencephalopathy. Management is supportive and symptomatic, focusing on physical therapy, management of spasticity, seizure control with antiepileptic medications, nutritional support, and multidisciplinary rehabilitation. Genetic counseling is recommended for affected families. Research into mitochondrial therapies and potential targeted treatments is ongoing but remains in early stages.
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Variable
Can begin at different ages, from infancy through adulthood
Treatments
No FDA-approved treatments are currently listed for Progressive cavitating leukoencephalopathy.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Progressive cavitating leukoencephalopathy at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Progressive cavitating leukoencephalopathy.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Progressive cavitating leukoencephalopathy.
Community
No community posts yet. Be the first to share your experience with Progressive cavitating leukoencephalopathy.
Start the conversation →Latest news about Progressive cavitating leukoencephalopathy
No recent news articles for Progressive cavitating leukoencephalopathy.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Progressive cavitating leukoencephalopathy
What is Progressive cavitating leukoencephalopathy?
Progressive cavitating leukoencephalopathy (PCL) is an extremely rare inherited neurological disorder characterized by progressive white matter deterioration (leukoencephalopathy) with the formation of cystic cavities (cavitations) in the brain. The disease primarily affects the central nervous system, with MRI findings showing diffuse white matter abnormalities and progressive cystic degeneration predominantly in the cerebral and cerebellar white matter. PCL has been associated with mutations in genes involved in mitochondrial function, including APOPT1 (also known as C14orf153) and genes enc
How is Progressive cavitating leukoencephalopathy inherited?
Progressive cavitating leukoencephalopathy follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.